784 related articles for article (PubMed ID: 26992841)
1. Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE.
Pieramici DJ; Wang PW; Ding B; Gune S
Ophthalmology; 2016 Jun; 123(6):1345-50. PubMed ID: 26992841
[TBL] [Abstract][Full Text] [Related]
2. Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials.
Boyer DS; Nguyen QD; Brown DM; Basu K; Ehrlich JS;
Ophthalmology; 2015 Dec; 122(12):2504-13.e1. PubMed ID: 26452713
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.
Reddy RK; Pieramici DJ; Gune S; Ghanekar A; Lu N; Quezada-Ruiz C; Baumal CR
Ophthalmology; 2018 Oct; 125(10):1568-1574. PubMed ID: 29752001
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
Brown DM; Nguyen QD; Marcus DM; Boyer DS; Patel S; Feiner L; Schlottmann PG; Rundle AC; Zhang J; Rubio RG; Adamis AP; Ehrlich JS; Hopkins JJ;
Ophthalmology; 2013 Oct; 120(10):2013-22. PubMed ID: 23706949
[TBL] [Abstract][Full Text] [Related]
5. Impact of Cataract Surgery during Treatment with Ranibizumab in Patients with Diabetic Macular Edema.
Moshfeghi AA; Shapiro H; Lemmon LA; Gune S
Ophthalmol Retina; 2018 Feb; 2(2):86-90. PubMed ID: 31047350
[TBL] [Abstract][Full Text] [Related]
6. Influence of Glycosylated Hemoglobin on the Efficacy of Ranibizumab for Diabetic Macular Edema: A Post Hoc Analysis of the RIDE/RISE Trials.
Bansal AS; Khurana RN; Wieland MR; Wang PW; Van Everen SA; Tuomi L
Ophthalmology; 2015 Aug; 122(8):1573-9. PubMed ID: 26050541
[TBL] [Abstract][Full Text] [Related]
7. Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema: Report From RESTORE, RIDE, and RISE Trials.
Bressler NM; Varma R; Mitchell P; Suñer IJ; Dolan C; Ward J; Ferreira A; Ehrlich JS; Turpcu A
JAMA Ophthalmol; 2016 Feb; 134(2):160-6. PubMed ID: 26584450
[TBL] [Abstract][Full Text] [Related]
8. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
Nguyen QD; Brown DM; Marcus DM; Boyer DS; Patel S; Feiner L; Gibson A; Sy J; Rundle AC; Hopkins JJ; Rubio RG; Ehrlich JS;
Ophthalmology; 2012 Apr; 119(4):789-801. PubMed ID: 22330964
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab.
Sophie R; Lu N; Campochiaro PA
Ophthalmology; 2015 Jul; 122(7):1395-401. PubMed ID: 25870079
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
Ip MS; Domalpally A; Sun JK; Ehrlich JS
Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
[TBL] [Abstract][Full Text] [Related]
11. Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials.
Domalpally A; Ip MS; Ehrlich JS
Ophthalmology; 2015 Apr; 122(4):779-86. PubMed ID: 25601535
[TBL] [Abstract][Full Text] [Related]
12. Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study.
Sepah YJ; Sadiq MA; Boyer D; Callanan D; Gallemore R; Bennett M; Marcus D; Halperin L; Hassan M; Campochiaro PA; Nguyen QD; Do DV;
Ophthalmology; 2016 Dec; 123(12):2581-2587. PubMed ID: 27707550
[TBL] [Abstract][Full Text] [Related]
13. Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration.
Stoller GL; Kokame GT; Dreyer RF; Shapiro H; Tuomi LL
JAMA Ophthalmol; 2016 May; 134(5):545-553. PubMed ID: 27010625
[TBL] [Abstract][Full Text] [Related]
14. Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-Label Extension of RIDE and RISE Studies.
Sun JK; Wang PW; Taylor S; Haskova Z
Ophthalmology; 2019 May; 126(5):712-720. PubMed ID: 30419298
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression.
Campochiaro PA; Khanani A; Singer M; Patel S; Boyer D; Dugel P; Kherani S; Withers B; Gambino L; Peters K; Brigell M;
Ophthalmology; 2016 Aug; 123(8):1722-1730. PubMed ID: 27236272
[TBL] [Abstract][Full Text] [Related]
16. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE.
Bressler NM; Varma R; Suñer IJ; Dolan CM; Ward J; Ehrlich JS; Colman S; Turpcu A;
Ophthalmology; 2014 Dec; 121(12):2461-72. PubMed ID: 25148789
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema.
Singh RP; Habbu K; Ehlers JP; Lansang MC; Hill L; Stoilov I
Ophthalmology; 2016 Jul; 123(7):1581-7. PubMed ID: 27234930
[TBL] [Abstract][Full Text] [Related]
18. The Clinical Importance of Changes in Diabetic Retinopathy Severity Score.
Ip MS; Zhang J; Ehrlich JS
Ophthalmology; 2017 May; 124(5):596-603. PubMed ID: 28284785
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
[TBL] [Abstract][Full Text] [Related]
20. Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose).
Do DV; Sepah YJ; Boyer D; Callanan D; Gallemore R; Bennett M; Marcus DM; Halperin L; Sadiq MA; Rajagopalan N; Campochiaro PA; Nguyen QD;
Eye (Lond); 2015 Dec; 29(12):1538-44. PubMed ID: 26228291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
